RxDoctor Payments DataLook up a doctor →

Rituxan: payments to doctors

Payments that named Rituxan as the associated drug or biological, reported under the Sunshine Act for program years 20192025.

Total reported
$67.5M
Providers
3,435
Transactions
18,107
Average per transaction
$3,727

The per-transaction average — $3,727 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,435 providers the average total is $19,646, but that average hides a very steep distribution.

Companies reporting these payments

CompanyTotal reportedShare
Genentech, Inc.$66,103,73998.0%
Genentech USA, Inc.$1,312,3481.9%
Bristol Myers Squibb$51,0360.1%
Chugai Pharmaceutical Co., Ltd.$11,3820.0%
F. Hoffmann-la Roche AG$6,3830.0%
Biogen$500.0%
← All drugs & devices